- Home
- NML vs SEPN Comparison
NML vs SEPN Comparison
Compare NML & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NML
- SEPN
- Stock Information
- Founded
- NML 2012
- SEPN 2022
- Country
- NML United States
- SEPN United States
- Employees
- NML N/A
- SEPN N/A
- Industry
- NML Finance/Investors Services
- SEPN
- Sector
- NML Finance
- SEPN
- Exchange
- NML Nasdaq
- SEPN NYSE
- Market Cap
- NML 500.9M
- SEPN 453.2M
- IPO Year
- NML N/A
- SEPN 2024
- Fundamental
- Price
- NML $8.71
- SEPN $11.67
- Analyst Decision
- NML
- SEPN Strong Buy
- Analyst Count
- NML 0
- SEPN 5
- Target Price
- NML N/A
- SEPN $26.75
- AVG Volume (30 Days)
- NML 219.3K
- SEPN 434.7K
- Earning Date
- NML 01-01-0001
- SEPN 08-15-2025
- Dividend Yield
- NML 9.75%
- SEPN N/A
- EPS Growth
- NML N/A
- SEPN N/A
- EPS
- NML N/A
- SEPN N/A
- Revenue
- NML N/A
- SEPN $977,000.00
- Revenue This Year
- NML N/A
- SEPN $3,429.67
- Revenue Next Year
- NML N/A
- SEPN N/A
- P/E Ratio
- NML N/A
- SEPN N/A
- Revenue Growth
- NML N/A
- SEPN 108.76
- 52 Week Low
- NML $6.09
- SEPN $4.17
- 52 Week High
- NML $7.33
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- NML 46.13
- SEPN N/A
- Support Level
- NML $8.72
- SEPN N/A
- Resistance Level
- NML $8.89
- SEPN N/A
- Average True Range (ATR)
- NML 0.12
- SEPN 0.00
- MACD
- NML -0.03
- SEPN 0.00
- Stochastic Oscillator
- NML 15.06
- SEPN 0.00
About NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States. Invest in Capital Markets, Chemicals, Oil, Gas & Consumable Fuels, Electric Utilities, Independent Power and Renewable Electricity Producers, Multi Utilities. Maximum is done in Oil, Gas & Consumable Fuels.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.